blood sampling
ProcedureExtra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
NCT Number: NCT03405402
Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and the sickle cell patients of African origin. Genetic and environmental risk factors have also been described.
The main risk factors that have been shown in retrospective or cross-sectional studies are some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the existence of an inflammatory event at the time of transfusion and the presence of anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the underlying immunological mechanism is not fully understood.
The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte alloimmunization and to try to understand the immunological mechanisms.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
CHU Brugmann, Brussels, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Sickle cell disease patients treated within the CHU Brugmann or Queen Fabiola Children's Hospital
Exclusion criteria
None
Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
Time frame: 1 hour before blood transfusion
Presence/abscence of irregular antibodies
Time frame: Between 2 to 4 weeks after blood transfusion
Presence/abscence of irregular antibodies
Time frame: 1 hour before blood transfusion
CRP dosage
Time frame: 1 hour before blood transfusion
Cytokine dosage
Time frame: Between 2 to 4 weeks after blood transfusion
Cytokine dosage
Time frame: 1 hour before blood transfusion
Heme oxygenase dosage
Time frame: Between 2 to 4 weeks after blood transfusion
Heme oxygenase dosage
Time frame: 1 hour before blood transfusion
Lymphocyte typing
Time frame: Between 2 to 4 weeks after blood transfusion
Lymphocyte typing
Time frame: 1 hour before blood transfusion
Sex
Time frame: 1 hour before blood transfusion
Blood transfusions planned at regular intervals of time (chronic transfusions) or performed in reaction to a medical issue (acute transfusion).
Time frame: 1 hour before blood transfusion
Medical reason explaining the necessity of a blood transfusion
Time frame: 1 hour before blood transfusion
Blood donor ethnicity
Hanane EL KENZ
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04691323
Anemia, Anemia, Hemolytic
Chicago, Illinois, United States
View Trial DetailsNCT04688411
Anemia, Anemia, Hemolytic
Chicago, Illinois, United States
View Trial DetailsNCT05405114
Anemia, Anemia, Hemolytic
Mobile, Alabama, United States
View Trial DetailsNCT07721155
Anemia, Anemia, Hemolytic
Amsterdam, Netherlands
View Trial Details